Intranasal COVID-19 interventions in clinical trials

With approvals in China, India, Iran and Russia, inhaled vaccines for COVID-19 are starting to see broad use; however, little data from these products have been made publicly available. A round-up of active intranasal programs in clinical development finds 12 programs that could help fill knowledge gaps, though most are early stage.

Inhaled vaccines and therapies can induce strong mucosal responses and are of particular interest for respiratory infections. They also enable needle-free, self-administration and storage at ambient temperatures, important features for global uptake. ...